Tilray Brands (TLRY) saw a surge in premarket trading after a U.S. government shift to reclassify certain marijuana products, leading to a rush into cannabis names. However, the move only applied to FDA-approved and state-licensed medical cannabis products, not the broader adult-use market. This move did not legalize marijuana nationally and did not resolve the broader federal conflict around adult-using cannabis. The company's shares initially jumped and then fell back, with shares including Tilray reversing. The move was seen as a sharper version of a pattern where policy headlines move the group quickly but the details often determine whether gains will stick. Despite this, Tilray's stock moved faster than the policy changes in slow motion. The firm still maintains a credible medical setup and has a strong business that includes medical cannabis, beverage alcohol, wellness, and pharmaceutical distribution.